<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002860'>Squamous cell carcinoma</z:hpo> (<z:mp ids='MP_0004207'>SCC</z:mp>) is the most common <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancer</z:e> in patients receiving immunosuppressive therapy, and is well documented to occur in patients that have undergone either solid organ transplantation or conventional myeloablative bone marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Nonmyeloablative hematopoietic cell transplantation (NMAT) provides transient, intensive immunosuppression, permitting allogeneic engraftment without ablating the marrow </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this report is to describe six patients that developed <z:mp ids='MP_0004207'>SCC</z:mp> (n=3), <z:hpo ids='HP_0002671'>basal cell carcinoma</z:hpo> (n=2), or <z:hpo ids='HP_0002861'>malignant melanoma</z:hpo> (n=2) over a period of 2-26 months following NMAT </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> prior to transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>The authors demonstrate for the first time that patients who undergo NMAT are at risk for developing <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancers</z:e> and emphasize the need for close surveillance in the post transplantation period </plain></SENT>
</text></document>